<DOC>
	<DOC>NCT01524302</DOC>
	<brief_summary>This study will further analyze the use of ceftaroline for CABP and compare its potential to eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of ceftaroline compared to levofloxacin may be further highlighted from this investigation.</brief_summary>
	<brief_title>Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>nonpregnant adults (â‰¥ 18 years old) with suspected CABP admitted to the hospital for parenteral antibiotic therapy. All patients will have a creatinine clearance (CrCl) &gt;50 ml/min. pregnant or nursing patients, allergy to penicillin/cephalosporin antibiotics, allergy to fluoroquinolones, renal or hepatic failure, or have received an antimicrobial in past 96h. Patients who require antibiotics other than the study drugs will also be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>pneumonia</keyword>
	<keyword>ceftaroline</keyword>
	<keyword>community-aquired</keyword>
</DOC>